Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900606 | 0.87 | ALDH1A1 (0.44) | POLBKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL19806100 | 0.86 | POLB (0.42) | POLBKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL29976335 | 0.86 | POLB (0.42) | POLBKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL19805997 | 0.82 | HTT (0.43) | POLBKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL5750658 | 0.82 | POLB (0.45) | POLBKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL62021 | 0.80 | POLB (0.53) | POLBKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL77207 | 0.80 | HSP90AA1 (0.55) | POLBKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL18343685 | 0.78 | HSP90AB1 (0.44) | POLBKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL602201 | 0.78 | ALDH1A1 (0.39) | POLBKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL10698921 | 0.76 | GAA (0.47) | KMT2AMEN1SMN1; SMN2GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4434982-A1 | (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2024-09-25 | — | — | EP | disclosed |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| CN-113272303-B | Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method and medical application thereof | 上海拓界生物医药科技有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118414332-A | (S) -2- (2-methylazetidin-1-yl) pyrimidine derivatives and pharmaceutical compositions containing the same | 株式会社LG化学 | 2024-07-30 | — | — | CN | disclosed |
| WO-2002088080-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1254119-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2002-11-06 | — | — | EP | disclosed |
| EP-1235812-A2 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002018374-A1 | SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001058881-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001038311-A2 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2001-05-31 | — | — | WO | disclosed |
| US-5726128-A | Benzyloxypyrimidine derivative, processes for producing the same and herbicidal composition | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-03-10 | — | — | US | disclosed |
| US-5723412-A | HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0707001-A1 | Benzyloxypyrimidine derivative, processes for producing the same and herbicidal composition | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-04-17 | — | — | EP | disclosed |
| EP-0694538-A2 | 2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and herbicidal composition containing the derivative | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | POLB 4449/4885KMT2A 4639/4885MEN1 4089/4885 |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | POLB 4449/4885KMT2A 4639/4885MEN1 4089/4885 |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | POLB 4449/4885KMT2A 4639/4885MEN1 4089/4885 |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | POLB 4802/4885KMT2A 1471/4885MEN1 1514/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | POLB 4449/4885KMT2A 4639/4885MEN1 4089/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | POLB 2686/4885KMT2A 3408/4885MEN1 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.